Table 4.
Drug acquisition costs for biologics in Finland
| Administration | Drug | Dose (mg) | Cost | Unit | Number of doses (first 3 months) |
|---|---|---|---|---|---|
| Subcutaneous | Secukinumab | 150 | €584.43 | Per prefilled syringe | 7.00 |
| Certolizumab pegol | 200 | €483.07 | Per prefilled syringe | 10.00 | |
| Etanercept | 50 | €260.04 | Per prefilled syringe | 13.00 | |
| Etanercept biosimilar | 50 | €182.02 | Per prefilled syringe | 13.00 | |
| Adalimumab | 40 | €527.41 | Per prefilled syringe | 7.00 | |
| Adalimumab biosimilar | 40 | €369.19 | Per vial | 7.00 | |
| Golimumab | 50 | €1,086.93 | Per prefilled syringe | 3.00 | |
| Intravenous | Infliximab | 100 | €436.06 | Per vial | 3.00 |
Notes: Finnish medicinal products and price database.27 All prices exclude value added tax. Retail price for s.c. products and wholesale price for i.v. products are applied according to local guidelines. Infliximab price was calculated as a weighted average according to market shares of originator drug and biosimilars. Additionally, a cost of €382 (2016 value) was considered for each i.v. administration.51 Biosimilar pricing for etanercept and adalimumab was assumed to be 30% less than brand; they are not available in the market and thus, only used for sensitivity analysis.
Abbreviations: i.v., intravenous; s.c., subcutaneous.